The pharmaceutical industry has moved past experimenting with artificial intelligence and is now treating it as essential infrastructure. Two major deals announced within days of each other this week reveal a fundamental shift: pharma companies are no longer asking whether AI can help them discover drugs; they are now investing billions to ensure they have the right algorithms and talent to stay competitive .

What Changed in Pharma's Approach to AI?

For years, pharmaceutical companies treated AI as a promising experimental tool. Today, the calculus has shifted entirely. The clearest evidence came from two blockbuster announcements. Anthropic, an AI safety company, acquired Coefficient Bio, a stealth biotech founded just eight months ago, for approximately $400 million in stock. Meanwhile, Insilico Medicine locked in a global research and development deal with Eli Lilly worth up to $2.75 billion in milestones, including $115 million due upfront .

What makes these deals significant is not just their size, but what they represent. Coefficient Bio's founding team came directly from Prescient Design, Genentech's internal computational drug discovery unit, and includes executives from Evozyne and Paragon Biosciences. This pattern reveals that pharma is no longer just licensing AI software; it is acquiring the people and expertise behind the algorithms. The Anthropic team will serve an existing pharma client base that already includes Sanofi, Novo Nordisk, AbbVie, and Genmab .

"Access to the right algorithms has become as strategically important to drug developers as the molecules they are chasing," noted the Drug Discovery News editorial team.

Drug Discovery News Editorial Team

This shift reflects a hard truth in modern drug discovery: computational power and machine learning models are now as valuable as traditional chemistry expertise. Companies that lack in-house AI capabilities or partnerships with leading AI firms risk falling behind competitors who can screen millions of molecular candidates in weeks rather than months.

How Is Regulatory Complexity Reshaping AI Drug Discovery?

While pharma companies race to acquire AI capabilities, they face a new obstacle: regulatory fragmentation, particularly in Europe. The European Union has implemented a comprehensive framework governing how AI systems can be used in healthcare and drug discovery, creating a divergent landscape from the United States .

The EU's approach rests on three pillars: the General Data Protection Regulation (GDPR), which governs how personal data is handled; the Artificial Intelligence Act, which classifies healthcare AI as high-risk and requires extensive oversight; and the European Health Data Space Regulation (EHDS), which controls how national health data can be accessed and used. Together, these rules impose significant governance obligations on AI systems, from training data provenance and model validation to post-deployment oversight .

The practical impact is substantial. The EU is shifting toward a federated data infrastructure model, which requires high-risk health data to be either segmented from non-EU data or stored locally within secure infrastructure environments. This change, which will come into force over the next five years, will reshape pharmaceutical research pipelines and create friction between diverging European and American approaches to data access .

• Data Transfer Restrictions: The ability to transfer European data outside the EU for pooled global datasets is now a legal liability, forcing companies to rethink how they structure global research collaborations.
• High-Risk Classification: Almost all health and pharmaceutical-related AI applications fall within the high-risk category under the EU AI Act, requiring regulation for not only specific AI outputs but also training data quality, provenance, and bias mitigation.
• Secure Processing Environments: The EHDS shifts the balance from transferring data outside the bloc to accessing data via secure processing environments within the EU, where AI systems must demonstrate compliance with both GDPR and the AI Act before accessing sensitive health information.
• Competitive Advantage for Compliant Firms: Well-resourced pharmaceutical companies that develop research pipelines complying with EU rules may access EU health data more reliably and engage with regulators more proactively, reducing legal uncertainty compared to smaller competitors.

This regulatory divergence creates both challenges and opportunities. Companies operating on both sides of the Atlantic must now maintain separate data infrastructure and governance protocols. However, firms that invest in EU-compliant AI systems early may gain a competitive edge in accessing Europe's vast health data repositories, which represent some of the world's most comprehensive patient records .

Steps to Navigate the Evolving AI Pharma Landscape

• Invest in Talent Acquisition: Rather than licensing AI tools alone, pharmaceutical companies should prioritize hiring or acquiring teams with deep expertise in computational drug discovery, as demonstrated by Anthropic's acquisition of Coefficient Bio.
• Build Regulation-by-Design Principles: Companies should embed regulatory compliance into their AI systems from the outset, particularly for operations in Europe, to avoid costly redesigns later as regulations tighten.
• Establish Federated Data Infrastructure: Pharma firms operating globally should develop secure, localized data processing environments that comply with both EU and US regulatory standards, rather than relying on centralized data repositories.
• Monitor Regulatory Evolution: The EU's Digital Omnibus Regulation Proposal, published in late 2025, aims to reduce regulatory burdens on AI and data protection, but negotiations are expected to continue into late summer 2026; companies should track these developments closely.

The geopolitical context adds another layer of complexity. Doubts over the sustainability of future EU-US data flows, as well as the rise of digital sovereignty as a policymaking priority within the 27-country EU bloc, make it difficult to navigate artificial intelligence and health data governance. The US and EU approaches to these topics are fundamentally different, and it remains unclear whether, in the short term, there is a path forward to reconcile these diverging regulatory and policymaking landscapes .

For investors and industry observers, the message is clear: the next wave of pharmaceutical innovation will be won not by companies with the best chemists, but by those with the best AI infrastructure, the most talented computational teams, and the regulatory agility to operate across fragmented global markets. The $2.75 billion Eli Lilly deal and Anthropic's $400 million acquisition are just the opening moves in what promises to be a much larger consolidation of AI talent and capabilities across the pharma industry.